GILD250117C87500
- 5.05
- +1.65+48.53%
Gilead Sciences Newsroom
Gilead Sciences, Inc. UK Regulatory Announcement: Form 8.3 - HOOKIPA Pharma Inc.
Express News | Gilead Exec Says Co Expects to Do "Something Like a CymaBay Acquisition Every Couple of Years" - JPM Healthcare Conf
Gilead Sciences: Supreme Court Case and New Innovations Drive Buy Rating
Express News | Morgan Stanley: raised the Target Price for Gilead Sciences from $87 to $113, and upgraded the rating from 'Neutral' to 'Shareholding.'
Gilead Sciences cooperates with LEO Pharma to develop projects for inflammatory diseases.
Gelonghui reported on January 13 that Gilead Sciences announced last Saturday that it has reached a collaboration with Denmark's LEO Pharma to develop a project for patients with inflammatory diseases. LEO Pharma will be eligible to receive up to $1.7 billion in payments, including a $0.25 billion upfront payment from Gilead. In return, Gilead will have the rights to develop, manufacture, and commercialize the small molecule oral STAT6 project globally. The statement noted that preclinical studies targeting STAT6 have shown potential in treating a wide range of inflammatory diseases, such as atopic dermatitis, asthma, and COPD. This Trade is expected to benefit Gilead.
Can 2025 J.P. Morgan Healthcare Conference Spark Biotech M&A?
Gilead in Pact for Anti-inflammatory Drugs in a Deal Worth up to $1.7B
Bernstein Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $105
Express News | Gilead has reached a collaboration with Leo Pharma.
Express News | Gilead - Transaction With Leo Pharma Is Expected to Reduce Gilead’s Gaap and Non-Gaap 2025 EPS by Approximately $0.15 - $0.17
Express News | Gilead - Leo Pharma Is Eligible to Receive up to $1.7 Billion in Total Payments, Including an Upfront Payment of $250 Million
Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
Bernstein Sticks to Its Buy Rating for Gilead Sciences (GILD)
Medicare Drug Prices Nearly Double, Surpassing Inflation: AARP
Gilead Upgraded by Morgan Stanley on Lenacapavir Potential
This McDonald's Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Redburn Atlantic Adjusts Price Target on Gilead Sciences to $125 From $123, Keeps Buy Rating
Today's Analyst Rating | Deutsche Bank Upgrades Boston Scientific to Buy, Morgan Stanley Upgrades Gilead Sciences to Buy
Jan 10, Wall Street analysts have updated their stock ratings today including $Boston Scientific(BSX.US)$ and $Gilead Sciences(GILD.US)$.
Gilead Sciences Analyst Ratings
Express News | Gilead Sciences Inc. : Morgan Stanley Raises to Overweight From Equal-Weight